Revision as of 01:24, 7 March 2021 by Elcatracho (talk | contribs) (See Also)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)


  • Type: Beta blocker
  • Dosage Forms: tablet, ophthalmic solution, ophthalmic suspension
  • Dosage Stregths: tablet: 10 mg, 20 mg; ophthalmic solution: 0.5%; ophthalmic suspension: 0.25%
  • Routes of Administration: PO, ophthalmic
  • Common Trade Names: Kerlone, Betoptic, Betoptic S

Adult Dosing

  • 5-80 mg PO daily
  • 1-2 drops in affected eye BID

Pediatric Dosing

Safety/efficacy of oral forms and 0.5% solution not established in peds

  • 0.25% suspension: 1 drop in affected eye BID

Special Populations

  • Pregnancy Rating: C; Caution advised in 2nd and 3rd trimesters. Risk of intrauterine growth restriction and neonatal adverse effects including bradycardia and hypoglycemia.
  • Lactation risk: L3; Safety unknown
  • Severe renal impairment: Start at 5mg PO daily, increase by 5mg/day q2wk to max daily dose 20mg
  • Hepatic dosing: no adjustment


Adverse Reactions




  • Half-life: 14-22 hr
  • Metabolism: Liver extensively; CYP450: Unknown
  • Excretion: Urine > 80% (15% unchanged)

Mechanism of Action

  • Selectively antagonizes beta-1 adrenergic receptors.


See Also